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Eli Lilly and Company is a pharmaceutical company that has the goal of creating new
products. Eli Lilly’s products are seen in hospitals and pharmacies around the US, with the hopes
of growing internationally. By having a large number of drugs in their pipeline, they can be a key
player in improving multiple types of illnesses as well as help aid the aging population. The
healthcare sector is always one that is high-performing.
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Eli Lilly and Company is positioned as a pharmaceutical company, with the goal of
creating high-quality medicine for every need or to take a preexisting medicine and make it
better. For the past 140 years, they have been creating medicine for various causes, but are now
focusing their efforts on antibody treatments for the COVID-19 pandemic, as well as different
cancers and autoimmune diseases. Everything that the company does should follow its core
values: integrity, excellence, and respect for people (Eli Lilly and Company - A). Eli Lilly is
found in the US, Japan, Europe, and hopes to expand to the rest of the world soon. They are
broken down into Endocrinology, Oncology, Immunology, Neuroscience, & Other. The company
has increased revenues from $23,832.8 - $25,925.3, a consistent tax rate of 15%, expenses
increasing $300k a year, accounts receivable, or a/r, decreasing as they pay less in patents and
drugs go generic, consistent inventory of $120k - $140k, showing they do not keep a lot on hand,
a weighted average cost of capital, or WACC, of 5.9% showing it does not hold a lot of debt, and
a long term growth rate of 2.3%, showing a healthy but stable growth (Bloomberg LP, CapitalIQ
2021).
While Eli Lilly is one of the largest pharmaceutical companies, they still face a lot of
competition from Big Pharma brands such as Johnson and Johnson, and smaller companies like
Merck, Pfizer, and Moderna. The healthcare sector is broken down into three industries:
Pharmaceuticals & Biotechnology - Where Eli Lilly is, Healthcare Facilities & Services, and
Medical Equipment & Devices (Scott, 2020). Eli Lilly tends to focus on acquiring other
companies to be able to expand upon the technology and name brands already created. They
have had 26 acquisitions, with the most recent being Prevail Therapeutics in 2020 for $880M
(Crunchbase). As of 2020, $6,086 million per year goes to R&D, which will provide more value
to their customers and shareholders (Eli Lilly and Company - F). They are one of the main
insulin manufacturers in the US, producing 11% of insulin, giving them negotiating power. The
top 3 pharmaceutical companies by market share include Merck at 4.44%, Johnson and Johnson
at 4.27%, and Eli Lilly at 2.57% (Bloomberg L.P).
Eli Lilly does have a sustained competitive advantage. For every drug that Eli Lilly
makes it costs $2.6B. The average length of the patent is 20 years, so they need to bring drugs to
the market before a company comes out with generics (Eli Lilly and Company - B). The biggest
thing that they did was create a generic version of their insulin product, Humalog, at a lower
price, since they believe that everyone with diabetes needs access to insulin (Keown, 2019). The
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graphs below show how each therapeutic area is performing compared to the whole, and how
operating expenses are rising each year. Advertising is decreasing as their products become more
well known, R&D is stable and increasing ever so slightly. Eli Lilly is outperforming its
competitors and
benchmark in their return
on investment.
The pharmaceutical
industry is mature with




Even with the pandemic,
they have seen $1.25T in
revenue (Mikulic, 2020).
According to the National Institute of Health, healthcare competition is high, with each company
trying to be the first to patent their products and secure patents before generics come out. During
the generic phase, companies try to deliver on price, quality, and brand name, or even technology
to reduce their costs (Rivers & Glover, 2008). Challenges in the industry life cycle include
increasing threats from competitors, not using technological advances properly, not taking risks,
and not having appealing advertising, compared to its competitors (Patil, 2018).
An opportunity that Eli Lilly has is political factors. After the riot at the capital, Eli Lilly
had to suspend some of its political donations (Hansard & Lee, 2021). With Biden’s new
stimulus package, people will have additional money to buy drugs, increasing Eli Lilly’s
customers and market share. The Lilly foundation improves global living standards (Eli Lilly &
Company - A). More people are currently being diagnosed as Covid long haulers (Hinton, 2021).
According to a Harvard Medical study, “50% to 80% of patients continue to have bothersome
symptoms three months after the onset of COVID-19,” and this number will continue to grow as
we find out more about the virus. Creating a drug that will help long haulers will have more of an
impact than just people who have Covid because it can be used at any time, and you do not have
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to have tested positive (Komaroff, 2020). While vaccines can help these symptoms, they do not
always do.
The image below shows that after they started testing their antibody drugs around May
2020, their stock price skyrocketed, revenues increased at a steady pace, and Earnings Per Share
has also increased. By using partnerships, they address global health challenges (FSG, 2018).
They also explore opportunities where an increasing number of patients are being diagnosed with
an illness with no cure. The increase of hybrid and electric cars can decrease shipping costs,
which they can reinvest into their company. They can increase their customer service by using
value strategies, getting to know their customers better, and improving their data analytics
(Kruse, 2019). As people are living longer, Eli Lilly can keep customers longer, while working
on diseases that affect the elder population like Alzheimer’s.
A threat that Eli Lilly has is lawsuits; a majority of their large drugs have been sued with
huge settlements (Eli Lilly & Co. - History and Product Lawsuits, 2020). Some settlements have
even made it to the supreme court (Blankenship, 2019). If Eli Lilly keeps getting sued, people
will shop elsewhere. On March 16th, 2021, Eli Lilly sued the Department of Health and Human
Services (HHS) government agency over “restricted sales of drugs discounted under the 340B
program to contract pharmacies, which are third parties that dispense the products on behalf of
the covered entities,” which the U.S. district court ruled in favor of Eli Lilly (King, 2021).
Counterfeits and low-quality products might appear in low-income markets. New technology
could hinder all of their progress. Since Eli Lilly is starting to appear internationally, they will
have to deal with political risk affecting the local currency and their spot rates.
Ardai 6
A strength that Eli Lilly has is partnering with companies to produce new products. They
have their medication in 125 countries, with 8,000 employees in 14 manufacturing sites (Eli Lilly
& Company - A). Their research team made sure all products were being produced at a rapid
pace - from zero to millions, “all while maintaining high quality standards” (Eli Lilly and
Company - J). They have high customer satisfaction, reliable suppliers, and customers to
overcome any shutdowns (Bloomberg L.P. 2021). They have a training program to make sure
that all their workers have access to the same information (Overman, 2011). So far, Eli Lilly has
performed well when entering new markets. Their new marketing manager has split their
advertising into television and digital channels (Bulik, 2019).
A weakness that Eli Lilly has is merging with firms that have a different culture than they
do. Their day’s inventory with a high of 329, is ahead of its peers at 224, meaning that they need
to raise more capital to invest in their products (Bloomberg L.P. 2021). They need to put more
money into technology and integrate their processes among all of their segments. For their
marketing, they are not unique compared to competitors. In 2009, they lost over 40% of their
revenue due to patent losses, forcing Eli Lilly to transform their business so they do not lose
customers to competitors or generics (Younglai, 2011). Eli Lilly needs to find a way to keep their
patents long term so their competitors do not copy their ideas, since the more long term a
company holds a patent for, the more monopolized their drugs will be, and with the high costs,
people will not want to buy from them anymore. Patents should “enable collaboration and
investment to bring forward tomorrow’s cures and allow us to move quickly and effectively”
(O'Neail & Eli Lilly & Company, 2021). Since Eli Lilly has some market share in each of their
segments, they can not be a leader in just one segment like some companies are. The chart below
shows the patents that will be expiring in the near future.
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Eli Lilly has human and financial resources. Their human resources department has the
employees try to reach their potential, try new things, and grow as a person (Eli Lilly &
Company - A). They hire people who will be an asset to their mission of creating the best drugs.
Their financial resources created the Eli Care Patient Assistant Program, providing free medicine
to those who need them (American Cancer Fund®, 2015). They are more concerned with
working with others across the world and accepting constructive criticism. In the past, they have
made some human resource adjustments that have positively impacted leadership and have
brought in more customers due to overcoming market skepticism. They have internal
capabilities, such as connected care, innovation, sales, and marketing. Their resource capabilities
are working more on their research and development, spending $6.086M last year, discouraging
new competitors (Statista, 2021).
In Porter’s five forces, the first is the threat of new entrants. In the pharmaceutical sector,
there are always companies trying to do something bigger and better than their competitors. They
can do it with lower costs, and need to build economies of scale. Eli Lilly has opened up an
innovation center, to create new products and services, and to make old products better to bring
new customers in and make existing customers want to stay (Eli Lilly and Company - D). By
spending $6,086M per year on R&D, this will keep less experienced competitors out and
discourages new competitors (Eli Lilly and Company - A). Even with the pandemic, they do not
see any issues affecting their supply chain and make sure they stay in close talk with their
suppliers (Manufacturing Chemist). They currently have 110 suppliers and 43 major customers
(Bloomberg LP). Eli Lilly uses multiple suppliers, as a safety net in case something happens with
their current suppliers. They currently distribute their products via wholesalers. The buyers have
the most say in the pharmaceutical industry since they want to buy their drugs at the cheapest
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cost. This forces Eli Lilly to try to build a large base of customers, so there will always be
someone to buy at their price. They can reinvest that money back into their company, creating
new products to discontinue current ones. The threat of substitutes forces Eli Lilly to not just
focus on their products, but to focus on their key values. They need to dig down deep to find out
why customers choose them, and if they leave, find out why they are leaving. All of the major
pharmaceutical companies are trying to be the best, despite rivalry among competitors. Eli Lilly
needs to be able to differentiate themselves, which they do with their generics, owning 11% of
the insulin market, and are constantly creating products for those illnesses with no cures (Eli
Lilly and Company - A). They have also successfully created the first approved antibody
treatment for COVID-19, which has other uses as well (Office of the Commissioner, 2020).
Instead of acquiring new companies, Eli Lilly should look at collaborating with other companies,
since that would be a mutually beneficial relationship.
Political factors that impact Eli Lilly include the Biden administration. According to a
recent article from PriceWaterhouse Coopers, Biden is focused on bringing prices down,
allowing for drug price negotiations, partnering with groups like the World Health Organization
for the development and production of new drugs, and bringing back the Affordable Care Act
(PricewaterhouseCoopers). Economical factors that affect Eli Lilly include working on their
supply chain to have a fewer number of higher quality suppliers, exposure to foreign currencies
with the hopes to go abroad, and market regulations (Eli Lilly and Company, 2020). For
environmental factors, they have become energy efficient by reducing their greenhouse gases
(Russell, 2020) Social factors that impact Eli Lilly include focusing on diversity inclusion,
including gender, race, or religion (Sprouls, 2018). They will work on increasing their diversity
in clinical trials since certain groups are currently underrepresented (Eli Lilly and Company - E).
The biggest technological factor that Eli Lilly needs to focus on is technology developments.
They invested $400M in their tech center for current production, but need to make sure their
future medicines are following these same advancements (Area Development News Desk, 2019).
For legal forces, they need to deal with potential lawsuits. Some of their well-known products
have led to an increased risk of issues, so they need to have money on hand just in case they are
sued. (Eli Lilly & Co. - History and Product Lawsuits, 2020).
Eli Lilly has had “over 135 years and a strong commitment to developing and discovering
new drugs in the areas of diabetes, neuroscience, cardiovascular diseases and oncology.”After
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researching and developing new products, they have a “vision to make a significant contribution
to humanity by improving global health in the 21st century” (Blake, 2016). They are a
top-performing pharmaceutical company while reinvesting the most money into R&D compared
to their competitors. They currently own 11% of the diabetes market, and with the aging
demographic, we expect more people to need diabetes care and are introducing a range of
generic drugs cheaper than competitors (Eli Lilly and Company - A). Eli Lilly hopes to grow
even more in the long term by producing more products that are more beneficial for their
customers. Eli Lilly is delivering drugs worldwide with solid financial results. Their drug
pipeline is constantly increasing, and they are expanding into new technologies like gene therapy
(Eli Lilly & Company - J). With the lessons learned from the COVID-19 pandemic, they can
apply those to any of their drugs.
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